Exelixis

COSMIC-312 | XL184-312

NCT03755791

JCP062

Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Subjects With Advanced HCC Who Have Not Received Previous Systemic Anticancer Therapy (COSMIC-312)

Status:

Closed to Accrual

26459-200.png

III

Phase

Line of Therapy.png

1st

Line of Therapy

Disease Stage.png

Advanced / Metastatic

Disease Stage

Target.png

Biomarker(s)

N/A

Investigational

Product

Cabozantinib

Tyrosine kinase inhibitor (p.o.)

Treatment Arms

o  Experimental: Experimental arm - cabozantinib + atezolizumab

o  Active Comparator: Control arm - sorafenib

o  Single-Agent Cabozantinib arm